(HealthDay)—For patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC) treated with pertuzumab and/or trastuzumab emtansine (T-DM1), a body mass index (BMI) of ≥30 kg/m² is associated with worse overall survival but does not affect progression-free survival to first-line chemotherapy (PFS1), according to a study published online Jan. 15 in the Journal of Cellular Physiology.
Read More
Health Rss 